CYP17 polymorphisms and prostate cancer outcomes.

Publication Type:

Journal Article

Source:

The Prostate, Volume 70, Issue 10, p.1094-101 (2010)

Keywords:

2010, Adult, Case-Control Studies, Center-Authored Paper, Cohort Studies, DISEASE PROGRESSION, DNA, Neoplasm, Genetic Predisposition to Disease, Genetic Variation, Genotype, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Polymerase Chain Reaction, Polymorphism, Single Nucleotide, Proportional Hazards Models, Prostatic Neoplasms, Public Health Sciences Division, Research Trials Office Core Facility - Biostatistics Service, SEER Program, Shared Resources, Specimen Processing Core Facility, Steroid 17-alpha-Hydroxylase, Washington

Abstract:

Cytochrome P450 17alpha-hydroxylases-C-(17,20)-lyase (CYP17) is a key enzyme involved with the androgen biosynthesis pathway and has recently been targeted for therapy in men with advanced prostate cancer (PCa). However, studies relating prostate cancer outcomes with CYP17 gene variants have conflicting results. In this study we analyzed Single Nucleotide Polymorphisms (SNPs) spanning the CYP17 gene for association with PCa survival.